Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Colon Cancer Stage III Clinical Trial

Official title:
mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study

Status Enrolling by invitation

Clinical Trial Summary

A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

Clinical Trial Description

After inclusion and exclusion criteria have been fulfilled and the patient consent has been obtained, the patient will be included and randomized to mFOLFIRINOX or mFOLFOX 6 with a 1:1 ratio. Arm A: mFOLFIRINOX Arm B: mFOLFOX ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05179889
Study type	Interventional
Source	Chungnam National University Hospital
Contact
Status	Enrolling by invitation
Phase	Phase 2/Phase 3
Start date	July 6, 2021
Completion date	March 15, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT00309530` - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C	Phase 3
Completed	`NCT04342676` - Lymph Node Ratio and Kras Mutation in R Colon Cancer	Phase 3
Withdrawn	`NCT05433402` - Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer	Phase 1/Phase 2
Recruiting	`NCT06108310` - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Withdrawn	`NCT05310565` - The Effects of Chiropractic in Adults With Colon Cancer	N/A
Not yet recruiting	`NCT04488159` - Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer	Phase 3
Recruiting	`NCT05194878` - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers	Phase 3